Abstract
In 1982 the Eastern Cooperative Oncology Group started a prospectively controlled, randomized trial in postmenopausal women with operable node positive breast cancer. The aim of the study was to compare the adjuvant efficacy of 4 cycles versus 12 cycles of chemotherapy as well as to evaluate the effect of long-versus short-term Tamoxifen. This is the first study directly evaluating the importance of Tamoxifen duration in an adjuvant setting. In addition to investigating duration of adjuvant treatment, the study was also designed to investigate the impact of pretreatment patient characteristics, namely the number of involved nodes and the hormone receptor status of the tumor, on disease-free interval and disease recurrence.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Falkson HC, Gray R, Wolberg WH, Gillchrist KW, Harris JE, Tormey DC, Falkson G (1990) Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous Tamoxifen versus 4 cycles of CMFPT in postmenopausal women with breast cancer: An ECOG phase III study. J Clin Oncol 8: 599–607
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag France
About this paper
Cite this paper
Falkson, H.C., Gray, R., Wolberg, W.H., Falkson, G. (1994). Follow-up results of an ECOG study of adjuvant therapy in post-menopausal women with breast cancer. In: Banzet, P., Holland, J.F., Khayat, D., Weil, M. (eds) Cancer Treatment An Update. Springer, Paris. https://doi.org/10.1007/978-2-8178-0765-2_30
Download citation
DOI: https://doi.org/10.1007/978-2-8178-0765-2_30
Publisher Name: Springer, Paris
Print ISBN: 978-2-8178-0767-6
Online ISBN: 978-2-8178-0765-2
eBook Packages: Springer Book Archive